Invention Grant
- Patent Title: Tricyclic inhibitors of poly(ADP-ribose)polymerase
-
Application No.: US16666307Application Date: 2019-10-28
-
Publication No.: US11248013B2Publication Date: 2022-02-15
- Inventor: Wang Shen , Jack Maung , Aimin Zhang , Xiaoling Zheng
- Applicant: Rakovina Therapeutics Inc.
- Applicant Address: CA Vancouver
- Assignee: Rakovina Therapeutics Inc.
- Current Assignee: Rakovina Therapeutics Inc.
- Current Assignee Address: CA Vancouver
- Agency: Morrison & Foerster LLP
- Main IPC: C07F9/6584
- IPC: C07F9/6584

Abstract:
The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.
Public/Granted literature
- US20200299315A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE Public/Granted day:2020-09-24
Information query